论文部分内容阅读
目的探讨伊托必利联合雷贝拉唑治疗反流性食管炎的临床效果。方法回顾性分析本院2013年4月—2014年12月收治的180例反流性食管炎患者的临床资料,将其按照就诊先后顺序分为观察组和对照组。给予对照组患者伊托必利口服,50mg/次,3次/d,雷尼替丁口服,150mg/次,2次/d;给予观察组患者伊托必利口服,50mg/次,3次/d,雷贝拉唑口服,10mg/次,2次/d。对比两组患者的临床治疗效果和不良反应发生情况。结果观察组患者临床症状改善总有效率为98.9%,明显高于对照组的75.6%,二者有显著性差异(P<0.05);治疗8周后,观察组患者胃镜下食管炎愈合总有效率为97.8%,明显高于对照组的73.3%,二者有显著性差异(P<0.05);两组患者均未出现严重不良反应。结论伊托必利联合雷贝拉唑治疗反流性食管炎有着较好的临床效果,能改善患者临床症状,促使食管炎愈合,且不良反应发生率低,安全性高,值得进行深入研究和推广。
Objective To investigate the clinical effect of itopride combined with rabeprazole in the treatment of reflux esophagitis. Methods The clinical data of 180 patients with reflux esophagitis treated in our hospital from April 2013 to December 2014 were retrospectively analyzed. The patients were divided into observation group and control group according to the order of their visits. The patients in the control group were given itop 50 mg orally, 3 times daily, ranitidine orally, 150 mg twice daily, and the patients in the observation group were given itop 50 mg once daily for 3 times / d, rabeprazole orally, 10mg / times, 2 times / d. The clinical efficacy and adverse reactions of two groups were compared. Results In the observation group, the total effective rate of clinical symptom improvement was 98.9%, which was significantly higher than that of the control group (75.6%) (P <0.05). After 8 weeks of treatment, the patients in the observation group had endoscopic esophagitis healing The efficiency was 97.8%, which was significantly higher than that of the control group (73.3%). There was a significant difference between the two groups (P <0.05). No serious adverse reactions occurred in both groups. Conclusion Itopride combined with rabeprazole has a good clinical effect in the treatment of reflux esophagitis, which can improve the clinical symptoms, promote the healing of esophagitis, and the incidence of adverse reactions is low and the safety is high, so it is worth further study. Promotion.